Patient-reported outcomes in acute graft-versus-host disease: optimizing patient care and clinical trial endpoints.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
25
09
2019
accepted:
25
02
2020
revised:
17
02
2020
pubmed:
12
3
2020
medline:
22
6
2021
entrez:
12
3
2020
Statut:
ppublish
Résumé
Patient-reported outcomes (PROs) refer to patient perceived and reported health-related quality of life (HRQOL), functional status, and symptom burden. PROs have become an important measure in oncologic care to identify the impact of the disease and its treatment on a patient's health status. Hematopoietic cell transplantation (HCT) is an aggressive and potentially curative therapy for patients with high-risk hematologic malignancies. A common complication of HCT is graft-versus-host disease (GVHD), which can be a significant contributor to morbidity and mortality, as well as a wide spectrum of physical and psychosocial effects. Quality of life and symptom burden have been shown to be important measures in the study of posttransplant complications, including chronic GVHD. We review the need for a novel tool in acute GVHD to capture disease symptoms and HRQOL to better understand patient symptoms, disease trajectory and outcome.
Identifiants
pubmed: 32157245
doi: 10.1038/s41409-020-0850-4
pii: 10.1038/s41409-020-0850-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533-1539Références
Lee SJ, Williams LA. Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials. Biol Blood Marrow Transplant. 2010;16:295–300.
pubmed: 19747556
doi: 10.1016/j.bbmt.2009.08.021
Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. J Am Med Assoc. 2002;288:3027–34.
doi: 10.1001/jama.288.23.3027
Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. J Am Med Assoc. 2017;318:197–8.
doi: 10.1001/jama.2017.7156
Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the patient‐reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6:522–31.
pubmed: 14627058
doi: 10.1046/j.1524-4733.2003.65309.x
Williams LA, Giralt SA, Wang XS, Mobley GM, Mendoza TR, Cohen MZ, et al. Measuring the symptom burden of allogeneic hematopoietic stem cell transplantation in patients with and without acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15:20–21.
doi: 10.1016/j.bbmt.2008.12.062
Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol. 2010;148:373–85.
pubmed: 19919651
doi: 10.1111/j.1365-2141.2009.07992.x
Shaw BE, Lee SJ, Horowitz MM, Wood WA, Rizzo JD, Flynn KE. Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN. Bone marrow Transplant. 2016;51:1173–9.
pubmed: 27159181
doi: 10.1038/bmt.2016.113
Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood. 2014;124:363–73.
pubmed: 24914140
pmcid: 4102709
doi: 10.1182/blood-2014-01-514786
Choi S, Reddy P. Graft-versus-host disease. Panminerva Med. 2010;52:111–24.
pubmed: 20517195
Atkinson K, Horowitz MM, Biggs JC, Gale RP, Rimm AA, Bortin MM. The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers. Bone Marrow Transplant. 1988;3:5–10.
pubmed: 3048470
Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53:1401–15.
pubmed: 29872128
pmcid: 6786777
doi: 10.1038/s41409-018-0204-7
Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512–8.
pubmed: 12931120
doi: 10.1016/S1083-8791(03)00162-9
Schoemans HM, Goris K, Van Durm R, Fieuws S, De Geest S, Pavletic SZ, et al. The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. Haematologica. 2018;103:1698–707.
pubmed: 29903762
pmcid: 6165809
doi: 10.3324/haematol.2018.190777
MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21:761–7.
pubmed: 25585275
pmcid: 4359643
doi: 10.1016/j.bbmt.2015.01.001
Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2:e21–9.
pubmed: 26687425
pmcid: 4340092
doi: 10.1016/S2352-3026(14)00035-0
Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846–55.
pubmed: 29545329
pmcid: 6014357
doi: 10.1182/blood-2018-01-822957
Hendriks MG, Schouten HC. Quality of life after stem cell transplantation: a patient, partner and physician perspective. Eur J Intern Med. 2002;13:52–56.
pubmed: 11836083
doi: 10.1016/S0953-6205(01)00198-4
Baca CB, Vickrey BG, Hays RD, Vassar SD, Berg AT. Differences in child versus parent reports of the child’s health-related quality of life in children with epilepsy and healthy siblings. Value Health. 2010;13:778–86.
pubmed: 20561342
pmcid: 3065295
doi: 10.1111/j.1524-4733.2010.00732.x
Duell T, van Lint MT, Ljungman P, Tichelli A, Socie G, Apperley JF, et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med. 1997;126:184–92.
pubmed: 9027268
doi: 10.7326/0003-4819-126-3-199702010-00002
Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N. Engl J Med. 1999;341:14–21.
pubmed: 10387937
doi: 10.1056/NEJM199907013410103
Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant. 1993;11:319–27.
pubmed: 8485479
Pidala J, Kurland BF, Chai X, Vogelsang G, Weisdorf DJ, Pavletic S, et al. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. Haematologica. 2011;96:1528–35.
pubmed: 21685473
pmcid: 3186315
doi: 10.3324/haematol.2011.046367
Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117:4651–7.
pubmed: 21355084
pmcid: 3099579
doi: 10.1182/blood-2010-11-319509
El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, et al. Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1341–8.
pubmed: 24813171
pmcid: 4127362
doi: 10.1016/j.bbmt.2014.05.001
Lee SJ, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:444–52.
pubmed: 12234170
doi: 10.1053/bbmt.2002.v8.pm12234170
Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, et al. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood. 2016;127:160–6.
pubmed: 26527676
pmcid: 4705606
doi: 10.1182/blood-2015-08-662874
Lee SJ, Williams LA. Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials. Biol Blood Marrow Transplant. 2010;16:295–300.
pubmed: 19747556
doi: 10.1016/j.bbmt.2009.08.021
Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114:7–19.
pubmed: 19336756
pmcid: 2710956
doi: 10.1182/blood-2008-10-182592
McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A, et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant. 1997;19:357–68.
pubmed: 9051246
doi: 10.1038/sj.bmt.1700672
Ware JE, Kosinski M, Dewey JE, Gandek B. SF-36 health survey: manual and interpretation guide. Lincoln, RI: QualityMetric Incorporated; 2000.
Altmaier EM, Ewell M, McQuellon R, Geller N, Carter SL, Henslee-Downey J, et al. The effect of unrelated donor marrow transplantation on health-related quality of life: a report of the unrelated donor marrow transplantation trial (T-cell depletion trial). Biol Blood Marrow Transplant. 2006;12:648–55.
pubmed: 16737938
doi: 10.1016/j.bbmt.2006.01.003
Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38:305–10.
pubmed: 16819438
doi: 10.1038/sj.bmt.1705434
Bolanos-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014;124:3221–7.
pubmed: 25170121
pmcid: 4239331
doi: 10.1182/blood-2014-06-577023
Wagner JE, Thompson JS, Carter SL, Kernan NA. Unrelated Donor Marrow Transplantation T. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366:733–41.
pubmed: 16125590
doi: 10.1016/S0140-6736(05)66996-6
Shaw BE, Syrjala KL, Onstad LE, Chow EJ, Flowers ME, Jim H, et al. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer. 2018;124:841–9.
pubmed: 29072787
doi: 10.1002/cncr.31089
Lee SJ, Onstad L, Chow EJ, Shaw BE, Jim HSL, Syrjala KL, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica. 2018;103:1535–41.
pubmed: 29858386
pmcid: 6119141
doi: 10.3324/haematol.2018.192930
Wood WA, Deal AM, Abernethy A, Basch E, Battaglini C, Kim YH, et al. Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:450–9.
pubmed: 23253558
doi: 10.1016/j.bbmt.2012.11.014
Wood WA, Deal AM, Bennett AV, Mitchell SA, Abernethy AP, Basch E, et al. Comparison of seven-day and repeated 24-hour recall of symptoms in the first 100 days after hematopoietic cell transplantation. J Pain Symptom Manag. 2015;49:513–20.
doi: 10.1016/j.jpainsymman.2014.06.011
Wood WA, Deal AM, Abernethy A, Basch E, Battaglini C, Kim YH, et al. Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:450–9.
pubmed: 23253558
doi: 10.1016/j.bbmt.2012.11.014
Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008;113:2102–9.
pubmed: 18792065
doi: 10.1002/cncr.23820
Rampey BD, Finnegan R, Goodman M, Mohadjer L, Krenzke T, Hogan J, et al. Skills of U.S. Unemployed, Young, and Older Adults in Sharper Focus: Results From the Program for the International Assessment of Adult Competencies (PIAAC) 2012/2014: First Look (NCES 2016-039). Washington, DC: U.S. Department of Education; 2016. http://nces.ed.gov/pubsearch . National Center for Education Statistics. Retrieved 6/10/2019.
Wu AW, Kharrazi H, Boulware LE, Snyder CF. Measure once, cut twice-adding patient-reported outcome measures to the electronic health record for comparative effectiveness research. J Clin Epidemiol. 2013;66 8 Suppl:S12–20.
pubmed: 23849145
pmcid: 3779680
doi: 10.1016/j.jclinepi.2013.04.005
Fox SaR, Lee. Part 1: How the internet has woven itself into American life. Pew Research Center. 2014.
Brundage M, Bass B, Davidson J, Queenan J, Bezjak A, Ringash J, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2011;20:653–64.
pubmed: 21110123
doi: 10.1007/s11136-010-9793-3
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1:100–7.
pubmed: 21350618
pmcid: 3043330
doi: 10.4103/0976-500X.72352
CONSORT Group Website. http://www.consort-statement.org . Accessed 9 Sept 2019.
Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. J Am Med Assoc. 2013;309:814–22.
doi: 10.1001/jama.2013.879
Rombach I, Jenkinson C, Gray AM, Murray DW, Rivero-Arias O. Comparison of statistical approaches for analyzing incomplete longitudinal patient-reported outcome data in randomized controlled trials. Patient Relat Outcome Measures. 2018;9:197–209.
doi: 10.2147/PROM.S147790
Rombach I, Rivero-Arias O, Gray AM, Jenkinson C, Burke O. The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literature. Qual Life Res. 2016;25:1613–23.
pubmed: 26821918
pmcid: 4893363
doi: 10.1007/s11136-015-1206-1
Rothrock NE, Kaiser KA, Cella D. Developing a valid patient-reported outcome measure. Clin Pharmacol Ther. 2011;90:737–42.
pubmed: 21975345
doi: 10.1038/clpt.2011.195